Tim Surgenor provides interim management and advisory services to the senior management teams of biotech companies that are experiencing rapid growth including entering commercialization stage. Tim has conducted strategic and commercial assessments and business development assignments for a number of biotechnology companies. He has advised Ironwood Pharmaceuticals on a number of topics including development of an inbound corporate development assessment process which has resulted in several recent deals including the acquisition of Zurampic from Astra Zeneca. He also has served as an advisor to Aldeyra Pharmaceuticals on portfolio planning, commercial assessment, and business development. Tim is a founder and managing partner of Red Sky and has more than 30 years of experience as an executive in large and small healthcare companies, with roles including head of business development, CFO, division president, CEO and board member.
Previously, Tim was Executive Vice President of Haemonetics, where he ran business development and global marketing and led numerous technology and company acquisitions. As President of Genzyme’s Tissue Repair Division, he led the worldwide launch of several cellular therapy products and was a member of the Genzyme Corporation investor relations and financing team. Tim has also served as CEO of Cyberkinetics, a publicly traded neurotechnology company and CFO of BioSurface Technology, a publicly traded cell therapy company. He is currently board member and audit committee chair of Neurometrix.
Tim has an MBA from the Harvard Graduate School of Business Administration a BA in Biochemistry from Williams College